On 2 December 2025, Celltrion announced that it has launched Remsima® SC (infliximab) in Chile, marking the biosimilar’s first entrance into the public market in Central and South America.
Remsima® SC was first listed on the Chilean public insurance plan in April 2025 and Celltrion Chile has recently completed its first sales following negotiations with the local public procurement agency, CENABAST. According to Celltrion, the public market accounts for 80% of pharmaceutical product sales in Latin America.
Celltrion’s Remsima®, biosimilar to Janssen’s Remicade® (infliximab), has been approved in Europe since 2013 and was launched in major European countries in early 2015. Subcutaneous infliximab (Remsima™ SC) first received European approval in November 2019 and was launched in the EU in 2020. In February 2024, Celltrion launched Remsima SC® as Zymfentra® in the US. In November 2025, Celltrion announced that its Remsima® IV liquid formulation was approved in Europe.